In aggregate, the data suggest a rationale for joint targeting of AR and EZH2 in prostate cancer because the latter reverts tumor cell progression towards a more androgen-dependent state and at the same time counteracts adaptive changes in macrophages and fibroblasts that are intimately linked to disease progression. Here, EZH2 is linked to prostate carcinoma.